Amedisys Company Insiders

AMED Stock  USD 92.64  0.07  0.08%   
Amedisys' insiders are aggressively selling. The analysis of insiders' sentiment of trading Amedisys stock suggests that all insiders are panicking at this time. Amedisys employs about 19 K people. The company is managed by 17 executives with a total tenure of roughly 35 years, averaging almost 2.0 years of service per executive, having 1117.65 employees per reported executive.
Paul Kusserow  CEO
CEO and President and Director
Michael North  President
Senior Vice President - Operations

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2023-03-03Michael Paul NorthDisposed 5908 @ 86.43View
2022-06-23Denise M BohnertDisposed 557 @ 115View
2022-03-29David L KemmerlyDisposed 2500 @ 177.31View
Monitoring Amedisys' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Amedisys' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Amedisys' future performance. Based on our forecasts, it is anticipated that Amedisys will maintain a workforce of about 19000 employees by April 2025.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Amedisys Management Team Effectiveness

The company has return on total asset (ROA) of 0.0624 % which means that it generated a profit of $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0332 %, meaning that it created $0.0332 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. At present, Amedisys' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.04, whereas Return On Assets are forecasted to decline to 0.01. At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 92.4 M, whereas Net Tangible Assets are projected to grow to (288.1 M).
The current year's Net Income Applicable To Common Shares is expected to grow to about 143.2 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 23.8 M.

Amedisys Workforce Comparison

Amedisys is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 274,548. Amedisys holds roughly 19,000 in number of employees claiming about 7% of equities under Health Care industry.

Amedisys Profit Margins

The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.520.4334
Fairly Up
Slightly volatile

Amedisys Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amedisys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amedisys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amedisys insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.75
6
8
 95,467 
 9,211 
2024-12-01
0.5
1
2
 10,421 
 14,586 
2024-09-01
0.5
1
2
 2,179 
 210.00 
2024-06-01
2.6667
8
3
 13,424 
 2,849 
2024-03-01
1.75
7
4
 98,702 
 6,551 
2023-12-01
0.2
1
5
 11,237 
 40,552 
2023-06-01
4.6667
14
3
 232,098 
 16,724 
2023-03-01
2.125
17
8
 99,314 
 24,861 
2022-06-01
0.7
7
10
 9,128 
 6,672 
2022-03-01
1.6154
21
13
 144,395 
 108,203 
2021-12-01
0.5
1
2
 1,000.00 
 1,200 
2021-06-01
0.5789
11
19
 9,667 
 17,951 
2021-03-01
0.661
39
59
 123,347 
 78,433 
2020-12-01
0.1935
6
31
 3,338 
 10,260 
2020-09-01
0.14
7
50
 508,635 
 760,284 
2020-06-01
0.2931
17
58
 45,392 
 82,985 
2020-03-01
0.5738
35
61
 160,189 
 145,868 
2019-12-01
0.3529
6
17
 8,389 
 26,256 
2019-06-01
0.4444
16
36
 40,907 
 85,855 
2019-03-01
1.5455
34
22
 372,156 
 70,678 
2018-12-01
0.381
16
42
 116,545 
 182,171 
2018-09-01
0.3333
3
9
 42,626 
 5,989 
2018-06-01
0.4194
13
31
 41,813 
 2,509,893 
2018-03-01
1.0625
17
16
 158,678 
 70,038 
2017-12-01
3.0
3
1
 17,656 
 7,866 
2017-09-01
0.8571
6
7
 4,126 
 5,217 
2017-06-01
0.4483
13
29
 40,028 
 123,635 
2017-03-01
2.3636
26
11
 364,839 
 61,150 
2016-12-01
0.1429
1
7
 6,875 
 29,597 
2016-06-01
0.3617
17
47
 38,765 
 188,997 
2016-03-01
3.3333
10
3
 185,967 
 12,251 
2015-12-01
0.2727
3
11
 130,000 
 694,303 
2015-09-01
0.5
1
2
 3,000 
 23,063 
2015-06-01
1.4444
13
9
 63,814 
 17,249 
2015-03-01
0.0476
1
21
 75,000 
 23,267 
2014-12-01
1.0
3
3
 350,000 
 11,355 
2014-09-01
1.5
6
4
 46,674 
 2,500 
2014-06-01
1.875
15
8
 768,818 
 13,568 
2014-03-01
0.4286
3
7
 10,090 
 2,263 
2013-12-01
2.0
12
6
 1,600,295 
 11,139 
2013-09-01
0.8333
5
6
 55,955 
 1,721 
2013-06-01
1.1429
16
14
 489,791 
 145,741 
2012-12-01
0.5
1
2
 1,334 
 2,041 
2012-09-01
0.8
4
5
 39,592 
 2,500 
2012-06-01
2.8
28
10
 171,732 
 55,144 
2012-03-01
2.0
6
3
 65,099 
 46,108 
2011-12-01
3.5
7
2
 53,648 
 13,560 
2011-06-01
0.8125
13
16
 135,186 
 59,628 
2011-03-01
1.0
3
3
 31,390 
 3,567 
2010-09-01
1.875
15
8
 55,824 
 30,759 
2010-06-01
0.8333
15
18
 47,539 
 20,379 
2010-03-01
0.4706
8
17
 49,817 
 63,065 
2009-12-01
0.4167
5
12
 18,300 
 48,911 
2009-09-01
0.5833
7
12
 31,180 
 104,508 
2009-06-01
1.4
7
5
 67,702 
 8,236 
2009-03-01
1.5
12
8
 123,088 
 69,469 
2008-12-01
2.0
6
3
 10,285 
 2,600 
2008-09-01
0.2941
5
17
 13,600 
 73,200 
2008-06-01
1.2143
34
28
 125,032 
 77,514 
2008-03-01
0.75
6
8
 41,484 
 26,600 
2007-12-01
0.4231
11
26
 44,207 
 155,156 
2007-09-01
5.0
5
1
 13,335 
 6,667 
2007-06-01
1.375
11
8
 87,697 
 64,286 
2007-03-01
0.5
5
10
 22,000 
 31,733 
2006-12-01
1.0
1
1
 13,334 
 0.00 
2006-09-01
1.6667
5
3
 12,273 
 12,697 
2006-03-01
4.75
19
4
 40,702 
 16,812 
2005-12-01
0.5
6
12
 22,166 
 44,657 
2005-09-01
0.3488
15
43
 99,395 
 276,972 
2005-06-01
0.3
3
10
 16,444 
 58,531 
2005-03-01
1.1667
7
6
 90,932 
 28,061 
2004-12-01
1.5
3
2
 116,667 
 1,485 
2004-09-01
0.6818
15
22
 50,000 
 150,330 
2004-03-01
0.0345
2
58
 15,291 
 667,641 
2003-12-01
0.0909
2
22
 40,000 
 165,527 
2003-09-01
12.0
12
1
 396,394 
 72,400 

Amedisys Notable Stakeholders

An Amedisys stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amedisys often face trade-offs trying to please all of them. Amedisys' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amedisys' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Richard AshworthCEO PresidentProfile
Paul KusserowCEO and President and DirectorProfile
Michael NorthSenior Vice President - OperationsProfile
Nick MuscatoVice President of Strategic FinanceProfile
Scott CPACOO, VPProfile
John NugentChief OfficerProfile
Pete HartleyCTO SystemsProfile
Kendra KimmonsVP RelationsProfile
Jennifer GriffinChief SecretaryProfile
Janet BrittVP CollectionsProfile
Francis MayerSenior DevelopmentProfile
Keith BlanchardActing OfficerProfile
Allyson GuidrozChief OfficerProfile
Scott GinnChief Accounting OfficerProfile
Denise BohnertChief OfficerProfile
Caitlin FranklinActing OfficerProfile
Adam HoltonChief OfficerProfile

About Amedisys Management Performance

The success or failure of an entity such as Amedisys often depends on how effective the management is. Amedisys management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amedisys management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amedisys management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.05  0.06 
Return On Capital Employed 0.06  0.06 
Return On Assets 0.02  0.01 
Return On Equity 0.04  0.04 
Please note, the presentation of Amedisys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amedisys' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amedisys' management manipulating its earnings.

Amedisys Workforce Analysis

Traditionally, organizations such as Amedisys use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amedisys within its industry.

Amedisys Manpower Efficiency

Return on Amedisys Manpower

Revenue Per Employee123.6K
Revenue Per Executive138.1M
Net Income Per Employee2K
Net Income Per Executive2.2M
Working Capital Per Employee6.2K
Working Capital Per Executive6.9M

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Global Correlations
Find global opportunities by holding instruments from different markets